Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A new regulatory acceptance for an oral version of semaglutide in China broadens Novo Nordisk’s potential market in the fast-growing GLP-1 obesity category, but Eli Lilly’s earlier filing suggests its competing pill could arrive first.
THE APEX TIMES
THE APEX TIMES
A fresh U.S. Food and Drug Administration approval is set to extend the reach of Mounjaro beyond glucose control, giving Eli Lilly a potential growth pathway in cardiovascular-risk management and raising the stakes for competition in metabolic disease drugs.
THE APEX TIMES
A reported FDA win is putting Eli Lilly’s Mounjaro back at center stage, after data cited in the coverage showed an 8% lower rate of major cardiovascular events compared with Lilly’s own diabetes drug Trulicity.
THE APEX TIMES
The biotech company said the larger-than-original debt sale will fund general corporate needs, including flexibility for its oncology plans and repayment of existing debt, alongside hedging actions tied to the notes.
THE APEX TIMES
Eli Lilly said the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) to lower the risk of major cardiovascular events in adults with type 2 diabetes, extending the obesity-and-diabetes drug’s role beyond glucose control.
THE APEX TIMES
A newly released industry report projects the cytotoxic drugs market rising from $16.21 billion in 2026 to $21.06 billion by 2031, citing improving access to cancer screening and treatment, including for oral therapies and newer drug formats.
THE APEX TIMES
FDA approvals for an updated COMIRNATY COVID-19 vaccine and progress on a Lyme disease effort are giving fresh momentum to arguments that Pfizer’s next phase of growth could depend less on legacy revenue and more on newer immunology and vaccine programs.
THE APEX TIMES
The FDA’s expanded approval of Imaavy adds a new treatment indication for warm autoimmune hemolytic anemia, a rare autoimmune blood disorder. Investors will be watching how Johnson & Johnson positions the therapy in a competitive, specialty hematology market.
THE APEX TIMES
The melanoma headline from Moderna and Merck pushed Tempus AI higher, intensifying debate over whether Tempus’ $1.5 billion purchase of Personalis is beginning to look strategically right. The companies have not laid out how quickly the clinical readout would translate into near-term revenue.
